drugset / Trial / NCT05739643

Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

NCT05739643 ↗

Phase 1/2 Active not recruiting 9 enrolled Forge Biologics, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a non-blinded, non-randomized dose escalation study of intravenous FBX-101 in which subjects will receive a single infusion of an adeno-associated virus gene therapy product, after more than 21 days of the HSCT (UCBT preferred HSCT source). Data from previously transplanted patients with infantile and late infantile Krabbe disease will be used as a comparator group.

Timeline

Start
2023-02-03
Primary completion
2026-11
Completion
2026-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject FBX-101 Gene therapy (AAV / viral vector) — Intravenous

Indications